This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Targeted gene therapy beneficial to mice with spinal muscular atrophy

March 15th, 2010

Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle wasting and weakness. The severity of the disease varies between individuals, with the clinical spectrum ranging from early infant death to normal adult life with only mild weakness. Currently, there are no effective therapies. As SMA is caused by mutations in the SMN1 gene that result in a lack of SMN protein, gene therapy provides one possible treatment strategy. Marco Passini and colleagues, at Genzyme Corporation, Framingham, now provide hope that this therapeutic approach might one day be possible by showing that in a severe mouse model of SMA they can substantially improve muscle strength, coordination, and locomotion by injecting the gene-carrying therapeutic directly into the brain and spinal cord of newborn mice.

More information:
View this article at: www.jci.org/articles/view/4161 … 87191885165c68a27202

Provided by Journal of Clinical Investigation

Citation: Targeted gene therapy beneficial to mice with spinal muscular atrophy (2010, March 15) retrieved 20 August 2026 from https://sciencex.com/wire-news/30132396/targeted-gene-therapy-beneficial-to-mice-with-spinal-muscular-at.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.